Screening of rural children in West Bengal for Fragile-X syndrome.
Studies carried out on Indian FRAXA patients show a frequency of ~7 per cent among mentally retarded males attending different types of outpatients (11-15). The present study was conducted to explore the occurrence of fragile X phenotype especially FRAXA amongst rural children of West Bengal to assist in early developmental intervention.
Material & Methods
Population screening: A three step screening programme was implemented for identification of FRAXA cases among the rural population of Sonarpur block, South 24 Parganas, in the State of West Bengal, India. The site was selected because of its close proximity to the organization and location of a branch office of Manovikas Kendra Rehabilitation and Research Institute for the Handicapped (MRIH) in that locality. Initially, all 11 Gram Panchayats in the Sonarpur block with an estimated population of 1,45,000, were targeted. Of these, 7 Gram Panchayats (population size ~ 80,250) actively participated in the programme and were screened for FRAXA. The remaining four Gram Panchayats were excluded from the study. Actual assessment was carried out on more than 38000 children in 7 Panchayats, with a fraction of 0.76 of estimated children. Elimination of four Gram panchayats may not have resulted in any bias because the study was designed to estimate the frequency of MR/FRAXA in the population actually screened which was done with a confidence interval of less than 0.4 (estimated sample size needed was 33767 with a 99% confidence at 0.4 confidence interval) (16).
At first, door-to-door survey for MR was conducted by a group of rural community workers, trained and employed by MRIH during 2004-2007 and details regarding age, sex, family income, nutritional status of the family, educational and medical status of family members, family history, maternal delivery history, birth details of children and present status of the affected individuals, if there is any were collected using a structured questionnaire.
At the second stage, data collected were analyzed by the mental health professionals to identify candidates for further screening. Inclusion criteria for selection at this stage were based on record of scholastic backwardness, developmental delay, clinical manifestation, cognitive disability, birth defect and family history of MR.
Recruitment of MR subjects: In the third and the final stage, a team of child psychiatrist, paediatrician, clinical psychologist and special educator examined the short-listed candidates. Mental health status was assessed following the Diagnostic and Statistical Manual of Mental Disorders--IV (17). IQ of children above 5 yr was measured by Wechsler Intelligence Scale for Children (18) and cases were classified as mild, moderate or severe on the basis of IQ. For children below 5 yr, developmental quotient (DQ) was measured as a ratio of the developmental age to the chronological age using the Developmental Screening Test (19) and those with DQ <85 were separately grouped under developmental delay (DD) category. The study protocol was approved by the Human Ethical Committee of MRIH.
Molecular analysis: Peripheral blood samples were collected from the cubital vein after obtaining informed written consent from the parents/guardians of the proband. Genetic testing for FRAXA was carried out for all the family members of MR cases recruited.
Detection of fragile X mental retardation protein (FMRP): Peripheral blood smear on glass slides were collected and stored at -20[degrees]C (<2 wk). Prior to staining, smear was fixed with 3 per cent paraformaldehyde (Sigma, USA) in phosphate buffer (pH 7.3), permeabilized with methanol (SRL, India) and immunostaining of peripheral blood lymphocytes (20,21) was carried out. Incubation with 1st antibody (goat FMRP-specific polyclonal antibody, Santa-Cruz Biotechnology, USA) was carried out for 2 h. A 2nd antibody (rabbit anti-goat-FITC conjugate, Santa-Cruz Biotechnology, USA) was added for 60 min at room temperature. Cells were viewed under Zeiss Axioskop 2 plus fluorescence microscope (Germany). For each slide, nearly 1000 cells were scored, and per cent of leukocytes exhibiting immunofluorescent staining (i.e., expressing FMRP) was calculated (Fig. 1).
Identification of CGG repeats: Genomic DNA was isolated by standard high salt precipitation method (22) from peripheral blood collected in EDTA and used for PCR amplification. Primer sequences used to amplify the CGG repeat region were procured from Sigma, USA. PCR amplification was carried out using Perkin Elmer thermal cycler (Gene Amp #2400, USA), in a final reaction volume of 20 [micro]l containing 75 ng of genomic DNA, 20 pmoles of each primer, 1.0 U Taq polymerase (Bangalore Genei, India), 200 [micro]TP mix (Bangalore Genei, India), 1X magic amplification solution (Bangalore Genei, India) 10 mM Tris buffer (NEB, USA) with 50 mM KCl and 2.0 mM Mg S[O.sub.4.] After an initial denaturation at 95[degrees]C for 5 min, amplification was performed for 35 cycle of denaturation at 94[degrees]C for 1 min, annealing at 68[degrees]C for 40 sec and extension at 74[degrees]C for 40 sec; cyclic reaction was followed by a final extension at 74[degrees]C for 5 min. PCR amplicons were analyzed by 12 per cent polyacrylamide gel electrophoresis and repeat sizes were determined using DNA marker (Fig. 2).
Determination of FMR1 gene promoter methylation: Analysis of methylation status of the FMR1 promoter and an internal control Xist gene (X-inactive specific transcript) was carried out following the method of Weinhausel and Hass (23). Genomic DNA (approximately 5 jig) was primarily deaminated using EZ DNA methylation kit (Zymo Research, USA) and was used for methylation analysis. PCR was carried out in a final reaction volume of 20 [micro]l containing 75 ng of deaminated DNA, 5 pmoles of each primer, 1.0 U Taq polymerase, (Bangalore Genei, India) 200 [micro]M dNTP mix, 1X Taq buffer B and 1.5 mM Mg[Cl.sub.2]. This PCR condition simultaneously amplified sequences of FMR1 and Xist gene (23). After an initial denaturation at 95[degrees]C for 5 min, amplification was performed for 35 cycle of denaturation at 95 [degrees]C for 30 sec, annealing at 60[degrees]C for 20 sec and extension at 72[degrees]C for 40 sec; cyclic reaction was followed by a final extension at 72[degrees]C for 7 min. Fragment sizes were analyzed by 2.5 per cent agarose gel electrophoresis (Fig. 3).
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
[FIGURE 3 OMITTED]
Cytogenetic analysis: Peripheral blood of probands, collected in heparin, was used to carry out lymphocyte culture in folate deficient as well as folate enriched RPMI 1640 media (Sigma, USA) (24) for detection of Xq27.3 deletion and other chromosomal abnormalities (25) respectively. Plasma or whole blood (0.5 ml), added to 4.5 ml of medium (Gibco BRL, USA) supplemented with 10 per cent foetal bovine serum (Gibco BRL, USA) and 100 ng phytohaemagglutinin (PHA-M, Gibco BRL, USA), was incubated for 69 h at 37[degrees]C in presence of 5 per cent C[O.sub.2] (Incubator, Heraeus, Germany). At the 69th h, 0.3 [micro]g of colcemid (N-deacetyl-Nmethylcolchicine; Gibco BRL, USA) was added to arrest cell division. Cultures were harvested after 45 min of colcemid treatment, subjected to centrifugation, treated with 0.075 M KCl solution (Merck, India) and incubated at 37[degrees]C for 25-min. It was centrifuged at 1000 g for 10 min, followed by fixation of cell pellet in Carnoy's fixative (methanol: acetic acid: 3:1) (SRL, India). Two to three subsequent washes in fixative were given to remove remaining cell debris.
GTG banding analysis (26) was carried out with fixed cells. Cells on glass slides were digested with 0.5 per cent trypsin (Difco, USA) and stained in 1 per cent Giemsa (BDH, India). Slides were air dried and viewed under oil-immersion lens of Zeiss Axioskop 2 plus microscope for evaluation. At least 50 well-spread metaphase plates were counted and dividing cells in late prophase/early metaphase with about 450 band resolutions were karyotyped using the karyoimager software (Carl Zeiss, Germany).
A total of 38,803 children and other members from 19,810 families were screened. Depending on the selection criteria, 179 children were short-listed for the final stage screening. Among these children, 147 were diagnosed as MR and others were found to have normal IQ but with various problems leading to scholastic backwardness (29 cases with bilateral hearing defect/ speech problem, 2 with affective disorder or conduct disorder, and 1 with attention deficit).
Of the 147 children with MR, 140 were identified as non-syndromic MR, and were further classified into developmental delay (n=20; DQ <85), mild (n=56; MiMR, IQ 66.03[+ or -]9.85), moderate (n=60; MoMR, IQ 45.93[+ or -]4.03) and severe MR (n=4; SMR, IQ 29.75[+ or -]1.71) categories. Remaining seven cases were identified as Down syndrome (DS, n=6) and cerebral palsy (n=1). Overall frequency of MR children in the studied population was approximately 4/1000 (147/38803); male: female ratio for MR was approximately 1.3 (age average 10.66 [+ or -] 4.84 yr).
Dysmorphic facial features were observed in <10 per cent cases (Table I). Speech problem was in about 36 per cent cases while hearing problem was observed in only a few (about 6%).
Analysis of leukocyte FMRP showed 46.58[+ or -]12.49 per cent positive cells in MR cases (Fig. 1; Table II). CGG repeat analysis revealed presence of 25 different alleles with repeat numbers varying between 13107 (Fig.2, Table II). Methylation analysis of FMR1 promoter and Xist genes revealed normal methylation pattern for both the genes (Fig. 3; Table II). Data obtained revealed 0 per cent frequency of FRAXA in the studied population with 0-0.02 per cent confidence interval.
During this rural screening programme for FRAXA frequency of MR was found to be low as (4/1000 i.e., about 0.4%). An unusually low frequency of SMR amongst rural children was also noticed (~ 0.1 per 1000) in contrast to the other developing countries with poor socio-economic status, where prevalence rate of SMR was found to be much higher (27) (> 5 per 1000 children). In our study, frequency of DS among live births was also very low (~0.15 per 1000 individuals) as compared to the global frequency (1.2/1000)28 and other studies (29,30) from India. Another observation was lack of any gross chromosomal abnormality in the 147 MR cases studied apart from six DS cases. Disorders like FRAXA, Huntington, bipolar disorder, attention deficit hyperactivity disorder, etc., which are known to have a genetic basis, were apparently absent. Whether this is due to rarity of these disorders in this rural population or is due to some other unknown factor is yet to be worked out.
A Kolkata-based study (n=158; 60 controls and 98 MR) reported 21 distinct normal CGG repeats (844) and among MR individuals, 7 per cent cases with higher repeats were confirmed as FRAXA (14). Studies from north India (predominantly Caucasoid population) revealed variations in the frequency of FRAXA amongst male MR cases. Studies on Delhi-based MR patients revealed about 8 per cent FRAXA (13,31) where as that from Lucknow showed 2.5 per cent prevalence (32). Another investigation on hospital-based samples revealed about 10 per cent FRAXA in Indian population of mixed origin (29). From the southern part of India, CGG repeat analysis of the FMR1 gene showed the 28 and 31 repeat alleles to be most predominant (11). In contrast, in our study, 25 alleles were observed with a variation in repeat sizes within 13-107; the 30 repeat allele was the most frequent (26.43%) followed by the 26 repeat (11.43%) and 28 repeat (10%) alleles. Frequency of FMRP positive leukocytes was more than 25 and methylation pattern was normal. Two individuals, who have CGG repeats in the premutation zone (ID 424 with 21/28/86/97 and ID 438 with 21/30/107 CGG repeats), also exhibited normal methylation pattern of the promoter and absence of any prominent clinical feature. All these findings point toward the absence of FRAXA in the studied population.
In conclusion, our findings indicate that the distribution pattern of CGG repeat is extremely heterogeneous even within the same ethnic group. The studied population had a low frequency of MR as compared to other parts of India and none had FRAXA. It would be interesting to study more people in the rural areas to validate our observation.
Authors acknowledge the Department of Biotechnology, New Delhi, for financial support. The first author (SD) thanks the Indian Council of Medical Research (ICMR), New Delhi, for providing senior research fellowship. Authors also thank the rural people and Gram Panchayat Pradhans and the rural community workers for active participation during the project.
Received October 17, 2007
(1.) Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001; 3 : 359-71.
(2.) Bennetto L, Pennington BF. The neuropsychology of fragile X syndrome. In: Hagerman RJ, Cronister A, editors. Fragile X syndrome: diagnosis, treatment and research. Baltimore: The Johns Hopkins University Press; 1996. p. 210-48.
(3.) Turner G, Daniel A, Frost M. X-linked mental retardation, macro-orchidism, and the Xq27 fragile site. J Pediatr 1980; 96 : 837-41.
(4.) Eichler EE, Richards S, Gibbs RA, Nelson DL. Fine structure of the human FMR1 gene. Hum Mol Genet 1993; 2 : 114753.
(5.) Hornstra IK, Nelson DL, Warren ST, Yang TP. High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome. Hum Mol Genet 1993; 2 : 165965.
(6.) Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000; 66 : 6-15.
(7.) Cleary JD, Pearson CE. Replication fork dynamics and dynamic mutations: the fork-shift model of repeat instability. Trends Genet 2005; 21 : 272-80.
(8.) Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65 : 905-14.
(9.) Pietrobono R, Tabolacci E, Zalfa F, Zito I, Terracciano A, Moscato UC, et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 2005; 14 : 267-77.
(10.) Oberle' I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991; 252 : 1097-102.
(11.) Baskaran S, Naseerullah MK, Manjunatha KR, Chetan GK, Arthi R, Rao GV, et al. Triplet repeat polymorphism & fragile X syndrome in the Indian context. Indian J Med Res 1998; 107 : 29-36.
(12.) Jain U, Verma IC, Kapoor AK. Prevalence of fragile X(A) syndrome in mentally retarded children at a genetics referral centre in Delhi, India. Indian J Med Res 1998; 108 : 12-6.
(13.) Sharma D, Gupta M, Thelma BK. Expansion mutation frequency and CGG/GCC repeat polymorphism in FMR1 and FMR2 genes in an Indian population. Genet Epidemiol 2001; 20 : 129-44.
(14.) Saha S, Karmakar P, Chatterjee C, Banerjee D, Das S, Dasgupta UB. Fragile X syndrome in Calcutta, India. Ann Clin Biochem 2001; 38 : 264-71.
(15.) Chakraborty SS, Mondal BC, Das S, Das K, Dasgupta UB. Haplotype analysis at the FRAXA locus in an Indian population. Am J Med Genet Part A 2008; 146 : 1980-5.
(16.) http://www.surveysystem.com/sscalc.htm, accessed on April 17, 2009.
(17.) American Psychiatric Association. Diagnostic and statistical manual for mental disorders, 4th ed. (DSM-IV). Washington DC (USA): American Psychiatric Association; 1994.
(18.) Wechsler D. Wechsler intelligence scale for children, 3rd ed. Manual. San Antonio, TX: Psychological Corporation; 1991.
(19.) Bharat Raj J. AIISH norms on SFB with Indian children. J All India Inst Speech Hearing 1971; 2 : 34-9.
(20.) Willemsen R, Mohkamsing S, de Vries B, Devys D, van den Ouweland A, Mandel JL, et al. Rapid antibody test for fragile X syndrome. Lancet 1995; 345 : 1147-8.
(21.) Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991; 66 : 817-22.
(22.) Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16 : 1215.
(23.) Weinhausel A, Haas OA. Evaluation of the fragile X (FRAXA) syndrome with methylation-sensitive PCR. Hum Genet 2001; 108 : 450-8.
(24.) Kahkonen M. Population cytogenetics of folate-sensitive fragile sites. I, Common fragile sites. Hum Genet 1988; 80 : 344-8.
(25.) Hungerford DA. Leukocytes cultured from small inocula of whole blood and the preparation of metaphase chromosomes by treatment with hypotonic KCl. Stain Technol 1965; 40 : 333-8.
(26.) Sun NC, Chu EH, Chang CC. Staining method for the banding patterns of human mitotic chromosomes. Caryologia 1974; 27 : 315-6.
(27.) Durkin M. The epidemiology of developmental disabilities in low-income countries. Ment Retard Dev Disabil Res Rev 2002; 8 : 206-11.
(28.) Chelly J, Khelfaoui M, Francis F, Cherif B, Bienvenu T. Genetics and pathophysiology of mental retardation. Eur J Hum Genet 2006; 14 : 701-13.
(29.) Verma IC. Burden of genetic disorders in India. Indian J Pediatr 2000; 67 : 893-8.
(30.) Varma N, Varma S, Marwaha RK, Malhotra P, Bansal D, Malik K, et al. Multiple constitutional aetiological factors in bone marrow failure syndrome (BMFS) patients from north India. Indian J Med Res 2006; 124 : 51-6.
(31.) Roy Chowdhury M, Kabra M, Sharma D, Singh D, Dabral A, Thelma BK, et al. Fragile X screening for FRAXA and FRAXE mutations using PCR based studies: results of a five year study. Indian J Hum Genet 2006; 12 : 17-22.
(32.) Pandey UB, Phadke S, Mittal B. Molecular screening of FRAXA and FRAXE in Indian patients with unexplained mental retardation. Genet Test 2002; 6 : 335-9.
Samikshan Dutta, Manali Das, Aneek Das Bhowmik, Swagata Sinha, Anindita Chattopadhyay & Kanchan Mukhopadhyay
Manovikas Biomedical Research & Diagnostic Centre, Kolkata, India
Reprint requests: Dr Kanchan Mukhopadhyay, Manovikas Biomedical Research & Diagnostic Centre, 482, Madudah
Plot I-24, Sec.-J, E.M. Bypass, Kolkata 700 107, India
Table I. Details of children with MR (n=147) No. of No. Malnutrition Co-morbid features children of Conduct/ Speech screened affected behavioral problem disorder 38,803 147 38 19 53 (25.85) (12.95) (36.05) Co-morbid No. of features Dysmorphic features children Hearing Elongated Hypertelorism screened problem face 38,803 9 7 10 (6.12) (4.76) (6.80) No. of Dysmorphic features children Ear Microcephaly Macrocephaly screened anomalies 38,803 14 10 1 (9.52) (6.80) (0.68) Most of the MR probands exhibited more than one clinical feature Values in parentheses are percentages Table II. Evaluation of MR cases for diagnosis of FRAXA No. of sample % of FMRP positive No. of CGG repeats Promoter leukocytes (range) (range) methylation status Male PM 179 46.58 [+ or -] 25 (13-107) -ve 12.5 (30-70) Promoter methylation No. of sample status Xq27.3 deletion Female PU PM PU 179 +ve +ve +ve None PM, fmr1 promoter methylated; PU, fmr1 promoter unmethylated; female have two X chromosomes, one active (unmethylated) and the other inactive (methylated). On the other hand, male have single X chromosome (unmethylated)
|Printer friendly Cite/link Email Feedback|
|Author:||Dutta, Samikshan; Das, Manali; Bhowmik, Aneek Das; Sinha, Swagata; Chattopadhyay, Anindita; Mukhopad|
|Publication:||Indian Journal of Medical Research|
|Date:||Dec 1, 2009|
|Previous Article:||Seroprevalence of subclinical HEV infection in pregnant women from north India: a hospital based study.|
|Next Article:||Changes in bone histology due to capacitive electric field stimulation of ovariectomized rat.|